CARA:NSD-Cara Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.95

Change

-0.10 (-0.66)%

Market Cap

USD 0.75B

Volume

0.15M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+8.61 (+3.95%)

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+5.74 (+1.13%)

USD54.24B 20.76 16.02
MRNA Moderna, Inc

+17.85 (+16.35%)

USD43.20B N/A N/A
SGEN Seagen Inc

+3.67 (+2.22%)

USD29.62B 62.48 65.81
ALXN Alexion Pharmaceuticals, Inc

+0.90 (+0.73%)

USD26.90B 28.53 26.40
RPRX Royalty Pharma plc

+0.63 (+1.54%)

USD25.62B 22.60 9.61
BNTX BioNTech SE

+5.03 (+4.79%)

USD25.27B -99,999.99 N/A
GMAB Genmab A/S

+1.22 (+3.40%)

USD23.59B 26.59 2.65
BGNE BeiGene, Ltd

+21.73 (+8.23%)

USD23.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CARA

Symbol Name Weight Mer Price(Change) Market Cap
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

+0.92 (+5.40%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.20% 44% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.20% 44% F 37% F
Trailing 12 Months  
Capital Gain -42.46% 18% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.46% 18% F 8% F
Trailing 5 Years  
Capital Gain -12.37% 59% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.37% 59% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 33.88% N/A N/A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.88% N/A N/A 86% B
Risk Return Profile  
Volatility (Standard Deviation) 72.05% N/A N/A 13% F
Risk Adjusted Return 47.02% N/A N/A 68% D+
Market Capitalization 0.75B 71% C- 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.98 34% F 23% F
Price / Cash Flow Ratio -6.87 53% F 75% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.34% 55% F 20% F
Return on Invested Capital -69.22% 44% F 14% F
Return on Assets -31.29% 41% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.64 29% F 16% F
Short Percent 8.71% 37% F 25% F
Beta 1.77 35% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector